Company Overview
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Lexington, Massachusetts. The company was founded with a focus on discovering and developing next-generation treatments for cystic fibrosis (CF) — a life-threatening genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that impair the protein's ability to regulate fluid transport in the lungs, digestive tract, and other organs. While Vertex Pharmaceuticals' Trikafta has transformed CF treatment for patients with the most common mutation (F508del), Sionna aims to develop modulators that more fully restore CFTR function and address patient segments not adequately covered by existing drugs.
Business Model & Competitive Advantage
Sionna has raised over $170M in total funding, including a $170M Series B in 2023 led by Foresite Capital and Novo Holdings, with participation from RA Capital Management and other life sciences investors. The company's lead program uses a novel small molecule approach to stabilize and potentiate CFTR protein function — going beyond the partial correction achieved by current modulators to achieve more complete restoration of ion channel activity. Sionna's science is built on insights into CFTR protein structure and conformational dynamics that have advanced significantly since Trikafta's development.
Competitive Landscape 2025–2026
Sionna competes primarily with Vertex Pharmaceuticals, which dominates the CFTR modulator market with Trikafta and its pipeline of next-generation combinations. Other competitors include Abbvie (through its partnership with Galapagos, now discontinued) and emerging biotech programs. Vertex's market dominance and regulatory track record make it a formidable incumbent. Sionna's case rests on the hypothesis that its mechanism can deliver meaningfully better efficacy or tolerability than Trikafta, either as a standalone or combination therapy — a hypothesis that will be tested in clinical trials.
Key Differentiators
Emerging Innovator
Sionna Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Sionna Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Sionna Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Sionna Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Sionna Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →